In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Alnylam Turnaround: What Changed Investors’ Minds?

Executive Summary

Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.

Advertisement

Related Content

How And Why Genzyme And Alnylam Expanded Their Alliance
Riding High On Investor Enthusiasm, BIO CEO 2014 Opens In New York
How And Why Genzyme And Alnylam Expanded Their Alliance
Alnylam CEO John Maraganore: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012
How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees
From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit
Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit
Roche Exits RNAi, Raising Questions For Stalwarts
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel